Pds biotech announces exclusive global license agreement for investigational il-12 tumor-targeted cytokine from merck kgaa, darmstadt, germany

Pds biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its versamune® platform

PDSB Ratings Summary

PDSB Quant Ranking